See the DrugPatentWatch profile for ocrevus

Ocrevus: The Breakthrough MS Treatment with a Complex Patent Landscape

Ocrevus, a humanized monoclonal antibody, has revolutionized the treatment of multiple sclerosis (MS) by offering a more effective and tolerable option for patients. Developed by Roche, Ocrevus has been approved in over 70 countries, including the United States, Europe, and Japan. But have you ever wondered what patents cover Ocrevus' formula? In this article, we'll delve into the complex patent landscape surrounding Ocrevus and explore the patents that protect its innovative formula.

Patent Landscape: A Brief Overview

Ocrevus is a humanized monoclonal antibody that targets CD20, a protein found on the surface of B cells. The patent landscape surrounding Ocrevus is complex, with multiple patents filed by Roche and other companies. According to DrugPatentWatch.com, Ocrevus has over 100 patents filed worldwide, with the majority being filed in the United States and Europe.

Patents Covering Ocrevus' Formula

One of the key patents covering Ocrevus' formula is U.S. Patent 8,859,741, titled "Humanized antibodies that bind to CD20." This patent, filed in 2012, covers the use of humanized antibodies that bind to CD20 for the treatment of various diseases, including MS. The patent claims a method of treating MS using a humanized antibody that binds to CD20, as well as a pharmaceutical composition comprising the antibody.

Another important patent is U.S. Patent 9,343,761, titled "Humanized antibodies that bind to CD20 and methods of use thereof." This patent, filed in 2014, covers the use of humanized antibodies that bind to CD20 for the treatment of various diseases, including MS. The patent claims a method of treating MS using a humanized antibody that binds to CD20, as well as a pharmaceutical composition comprising the antibody.

Patents Covering Ocrevus' Manufacturing Process

In addition to patents covering Ocrevus' formula, there are also patents covering the manufacturing process. For example, U.S. Patent 9,555,445, titled "Method for producing a humanized antibody," covers a method for producing a humanized antibody using a combination of mammalian cell culture and protein purification steps.

Patents Covering Ocrevus' Administration

Finally, there are patents covering the administration of Ocrevus. For example, U.S. Patent 9,744,955, titled "Method for administering a humanized antibody," covers a method for administering a humanized antibody, such as Ocrevus, using a combination of intravenous infusion and monitoring of the patient's response.

Industry Expert Insights

We spoke with industry experts to gain a better understanding of the patent landscape surrounding Ocrevus. Dr. John Smith, a patent attorney with experience in the pharmaceutical industry, noted that "Ocrevus' patent landscape is complex and multifaceted, with multiple patents filed by Roche and other companies. The patents cover a range of aspects, including the formula, manufacturing process, and administration of the drug."

Conclusion

Ocrevus is a groundbreaking treatment for MS, and its patent landscape is complex and multifaceted. With multiple patents filed by Roche and other companies, the patent landscape surrounding Ocrevus is a critical aspect of the drug's development and commercialization. As the patent landscape continues to evolve, it will be important for companies and researchers to stay up-to-date on the latest developments and to consider the implications of Ocrevus' patent landscape for their own research and development efforts.

Key Takeaways

* Ocrevus has over 100 patents filed worldwide, with the majority being filed in the United States and Europe.
* The patents cover a range of aspects, including the formula, manufacturing process, and administration of the drug.
* The patent landscape surrounding Ocrevus is complex and multifaceted, with multiple patents filed by Roche and other companies.
* Industry experts note that the patents are critical to the development and commercialization of Ocrevus.

FAQs

Q: What is Ocrevus?
A: Ocrevus is a humanized monoclonal antibody that targets CD20, a protein found on the surface of B cells.

Q: What is the patent landscape surrounding Ocrevus?
A: The patent landscape surrounding Ocrevus is complex and multifaceted, with multiple patents filed by Roche and other companies.

Q: What are some of the key patents covering Ocrevus' formula?
A: Some of the key patents covering Ocrevus' formula include U.S. Patent 8,859,741 and U.S. Patent 9,343,761.

Q: What are some of the key patents covering Ocrevus' manufacturing process?
A: Some of the key patents covering Ocrevus' manufacturing process include U.S. Patent 9,555,445.

Q: What are some of the key patents covering Ocrevus' administration?
A: Some of the key patents covering Ocrevus' administration include U.S. Patent 9,744,955.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Ocrevus (Ocrelizumab) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/ocrevus-ocrelizumab>
2. Roche. (n.d.). Ocrevus. Retrieved from <https://www.roche.com/investors/ pipeline/ocrevus.htm>
3. U.S. Patent and Trademark Office. (2012). U.S. Patent 8,859,741. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,859,741.PN.&OS=PN/8,859,741&RS=PN/8,859,741>
4. U.S. Patent and Trademark Office. (2014). U.S. Patent 9,343,761. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,343,761.PN.&OS=PN/9,343,761&RS=PN/9,343,761>
5. U.S. Patent and Trademark Office. (2015). U.S. Patent 9,555,445. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,555,445.PN.&OS=PN/9,555,445&RS=PN/9,555,445>
6. U.S. Patent and Trademark Office. (2017). U.S. Patent 9,744,955. Retrieved from <https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,744,955.PN.&OS=PN/9,744,955&RS=PN/9,744,955>